Phase II Open-Label, Non-Randomized, Multicenter Study of Interstitial 131I-chTNT-1/B for the Treatment of Newly Diagnosed or Recurrent Malignant Glioma.

Trial Profile

Phase II Open-Label, Non-Randomized, Multicenter Study of Interstitial 131I-chTNT-1/B for the Treatment of Newly Diagnosed or Recurrent Malignant Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2011

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top